|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,277.00 JPY | +0.40% |
|
+1.23% | +9.14% |
| May. 14 | Takeda Pharmaceutical Settles DOJ's Kickback Case for $13.7 Million -- Update | DJ |
| May. 14 | Takeda Pharmaceutical Settles DOJ's Kickback Case for $13.7 Million | DJ |
Company Valuation: Takeda Pharmaceutical Company Limited
Data adjusted to current consolidation scope
| Fiscal Period: March | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 6,229,971 | 5,423,454 | 6,762,204 | 6,564,378 | 6,749,675 | 8,303,626 | - | - |
| Change | - | -12.95% | 24.68% | -2.93% | 2.82% | 23.02% | - | - |
| Enterprise Value (EV) 1 | 9,862,522 | 8,919,170 | 10,611,015 | 10,950,330 | 10,725,175 | 12,243,341 | 12,033,834 | 11,807,146 |
| Change | - | -9.57% | 18.97% | 3.2% | -2.06% | 14.16% | -1.71% | -1.88% |
| P/E ratio | 16.6x | 23.8x | 21.3x | 45.4x | 64.6x | 46.4x | 38.5x | 26.7x |
| PBR | 1.2x | 0.95x | 1.06x | 0.9x | 1x | 1.15x | 1.16x | 1.16x |
| PEG | - | -0.6x | 0.5x | -0.8x | -2.5x | 0.6x | 1.8x | 0.6x |
| Capitalization / Revenue | 1.95x | 1.52x | 1.68x | 1.54x | 1.47x | 1.99x | 1.81x | 1.79x |
| EV / Revenue | 3.08x | 2.5x | 2.63x | 2.57x | 2.34x | 2.7x | 2.62x | 2.54x |
| EV / EBITDA | 9.23x | 8.54x | 9.19x | 11.6x | 9.71x | 9.97x | 9.5x | 8.76x |
| EV / EBIT | 19.4x | 19.4x | 21.6x | 51.1x | 31.3x | 28.3x | 25.4x | 20.2x |
| EV / FCF | 16x | 8.92x | 28.7x | 43.4x | 15.5x | 14.5x | 10.8x | 15.7x |
| FCF Yield | 6.26% | 11.2% | 3.49% | 2.31% | 6.43% | 6.9% | 9.27% | 6.36% |
| Dividend per Share 2 | 180 | 180 | 180 | 188 | 196 | 200 | 203.6 | 207.3 |
| Rate of return | 4.52% | 5.15% | 4.14% | 4.49% | 4.44% | 3.81% | 3.87% | 3.94% |
| EPS 2 | 240.7 | 147.1 | 204.3 | 92.09 | 68.36 | 122 | 136.6 | 197 |
| Distribution rate | 74.8% | 122% | 88.1% | 204% | 287% | 178% | 149% | 105% |
| Net sales 1 | 3,197,812 | 3,569,006 | 4,027,478 | 4,263,762 | 4,581,600 | 4,505,700 | 4,598,749 | 4,649,390 |
| EBITDA 1 | 1,068,940 | 1,043,995 | 1,154,905 | 942,077 | 1,103,982 | 1,129,888 | 1,266,233 | 1,347,095 |
| EBIT 1 | 509,269 | 460,844 | 490,505 | 214,100 | 342,600 | 408,800 | 473,659 | 585,960 |
| Net income 1 | 376,005 | 230,059 | 317,017 | 144,067 | 107,900 | 191,800 | 215,403 | 304,116 |
| Net Debt 1 | 3,632,551 | 3,495,716 | 3,848,811 | 4,385,952 | 3,975,500 | 3,939,715 | 3,730,208 | 3,503,520 |
| Reference price 2 | 3,985.00 | 3,498.00 | 4,350.00 | 4,184.00 | 4,413.00 | 5,256.00 | 5,256.00 | 5,256.00 |
| Nbr of stocks (in thousands) | 1,563,355 | 1,550,444 | 1,554,530 | 1,568,924 | 1,529,498 | 1,579,838 | - | - |
| Announcement Date | 5/11/21 | 5/11/22 | 5/11/23 | 5/9/24 | 5/8/25 | 5/13/26 | - | - |
1JPY in Million2JPY
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 46.2x | 2.68x | 9.89x | 3.85% | 51.96B | |
| 29.8x | 10.81x | 22.32x | 0.67% | 906B | |
| 24.63x | 5.68x | 15.43x | 2.32% | 555B | |
| 25.42x | 6.28x | 12.82x | 3.29% | 368B | |
| 16.92x | 4.24x | 10.45x | 3.13% | 326B | |
| 23.43x | 4.86x | 13.81x | 1.79% | 289B | |
| 20.6x | 5.55x | 13.49x | 3.01% | 285B | |
| 50.61x | 4.74x | 19.25x | 2.94% | 280B | |
| 13.54x | 4.96x | 10.13x | 3.73% | 208B | |
| 21.88x | 5.9x | 10.3x | 3% | 182B | |
| Average | 27.30x | 5.57x | 13.79x | 2.77% | 345.04B | |
| Weighted average by Cap. | 26.53x | 6.72x | 15.83x | 2.27% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- 4502 Stock
- Valuation Takeda Pharmaceutical Company Limited
Select your edition
All financial news and data tailored to specific country editions
